The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical practice.
Study Type
OBSERVATIONAL
Enrollment
1,128
Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
Pfizer Local Country Office
Tokyo, Japan
Number of Participants with adverse drug reactions
Time frame: 156 weeks
Number of Participants with Discontinuation of Treatment
Time frame: 156 weeks
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score
IGA Scores: Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( \>=2) Points at Week X: Non-responder Imputation
Time frame: Baseline, 156 weeks
Percentage of Participants with Change From Baseline in Eczema Area and Severity Index (EASI)
Time frame: Baseline, 156 weeks
Percentage of Participants with Change From Baseline in Affected % Body Surface Area (BSA)
Time frame: Baseline, 156 weeks
Percentage of Participants with Change From Baseline in Pruritus Assessment
Time frame: Baseline, 156 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.